|Bid||5.12 x 3100|
|Ask||5.57 x 3200|
|Day's range||5.25 - 5.50|
|52-week range||3.37 - 7.70|
|Beta (5Y monthly)||2.12|
|PE ratio (TTM)||N/A|
|Earnings date||03 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.83|
If you want to know who really controls Adaptimmune Therapeutics plc ( NASDAQ:ADAP ), then you'll have to look at the...
Biotech stocks have been some of the most reliable capital-appreciation vehicles in the entire market for the past two decades. As proof, biotech equities such as CRISPR Therapeutics, Moderna, Novavax, Ocugen, and Vertex Pharmaceuticals -- just to name a few -- have all made their early shareholders market-crushing gains. Not all biotech stocks are cut from the same cloth, however.
Adaptimmune (ADAP) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.